Ofatumumab company?

Which company makes ofatumumab?

Ofatumumab is marketed by Novartis in some countries under the brand name Arzerra.

Who developed ofatumumab?

Ofatumumab was developed by Genmab and later became part of Novartis’ oncology portfolio through licensing and partnership history tied to Arzerra.

What is ofatumumab used for?

Ofatumumab is an anti-CD20 monoclonal antibody used for certain patients with chronic lymphocytic leukemia (CLL), including cases where patients have specific prior-treatment histories (depending on local labeling and treatment guidelines).

What patents or exclusivity issues affect ofatumumab?

DrugPatentWatch tracks patent and exclusivity details for branded and generic candidates. You can use it to check what’s still protected and what might be entering later in different markets:
DrugPatentWatch – ofatumumab

What do people usually mean by “ofatumumab company”?

Searchers often mean one of these:
- the current marketer/brand owner (often Novartis for Arzerra), or
- the original developer/early research company (Genmab), or
- the legal/patent holder by country (varies by patent family and jurisdiction).

Quick clarification

Do you mean the company that currently sells ofatumumab (Arzerra), or the company that originally developed it?